Kiniksa Pharmaceuticals International Plc(KNSA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | RUT | P/E | 77.55 | EPS (ttm) | 0.98 | Insider Own | 42.3% | Shs Outstand | 48.2M | Perf Week | -5.22% |
| Market Cap | 5.95B | Forward P/E | 37.18 | EPS next Y | 47.3% | Insider Trans | -2.07% | Shs Float | 45.0M | Perf Month | -2.41% |
| Enterprise Value | 5.43B | PEG | 0.68 | EPS next Q | 0.37 | Inst Own | 60.27% | Short Float | 8.42% | Perf Quarter | 47.87% |
| Income | 0.08B | P/S | 7.08 | EPS this Y | 85.7% | Inst Trans | 1.72% | Short Ratio | 5.13 | Perf Half Y | 65.55% |
| Sales | 0.84B | P/B | 9.09 | EPS next 5Y | 54.65% | ROA | 10.36% | Short Interest | 3.79M | Perf YTD | 84.9% |
| Book/sh | 8.39 | P/C | 11.31 | EPS past 3/5Y | -34.04% - | ROE | 14.04% | 52W High | -8.04% ($82.94) | Perf Year | 106.08% |
| Cash/sh | 6.74 | P/FCF | 32.55 | Sales past 3/5Y | 45.45% - | ROIC | 12.24% | 52W Low | 116.68% ($35.20) | Perf 3Y | 337.58% |
| Dividend Est. | - | EV/EBITDA | 53.25 | EPS Y/Y TTM | 1646.61% | Gross Margin | 54.45% | Volatility(W/M) | 3.62% 3.02% | Perf 5Y | 515.08% |
| Dividend TTM | - | EV/Sales | 6.46 | Sales Y/Y TTM | 58.85% | Oper. Margin | 11.92% | ATR (14) | 2.65 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.49 | EPS Q/Q | 33.3% | Profit Margin | 9.59% | RSI (14) | 48.52 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.9 | Sales Q/Q | 55.36% | SMA20 | -3.11% ($78.72) | Beta | 0.04 | Target Price | $98 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/7/28 | SMA50 | 4.38% ($73.07) | Rel Volume | 0.48 | Prev Close | $76.48 |
| Employees | 366 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 0.17% 7.56% | SMA200 | 42.32% ($53.59) | Avg Volume(3M) | 0.74M | Price | $76.27 |
| IPO | 2018/5/24 | Option/Short | Yes/Yes | Trades | 6295 | Volume | 358,022 | Change | -0.27% |
Company
KNSA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 A commercial-stage biopharmaceutical company that sells treatments for rare autoimmune and cardiovascular diseases. It commercializes and sells therapies indicated for conditions including recurrent pericarditis, generating stable, profit-based revenues while pursuing pipeline expansion. A biopharmaceutical company specializing in rare diseases.
Over the past 1 year, on the higher side
8% below its 1-year high.
KNSA makes money exceptionally well
Strong earnings and excellent financial health
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +85.7% this year.
Tap to view numbers
The price looks about right
Trading at 77.5 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +337.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 60.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
BBP 0.02%
FMED 0.01%
HYP 0.01%
FDLS 0.01%
SGRW 0.01%It ranks #4 in the industry
Based on market cap of $6B.
KNSA $6B PER 77.5
TAK $58B PER -
TEVA $43B PER 62.4
HLN $40B PER 18.9
FAQ
What kind of company is KNSA?
KNSA belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of KNSA?
The market cap of KNSA is approximately $6.0B, ranking 1,258 within its sector.
What is the P/E ratio of KNSA?
KNSA has a P/E ratio of approximately 77.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for KNSA?
KNSA has recorded a 52-week high of $82.94 and a low of $35.20.
